ProThera Biologics competitors

Barry Kappel is a Board Member at Sapience Therapeutics Inc and Founder, President and CEO at Sapience Therapeutics Inc and is based in New York City, New York. He has worked as Senior Consultant at Easton Associates, Senior Vice President Business Development at CONTRAFECT CORP, and Lab Manager and Senior Research Technician at Memorial Sloan - Kettering Cancer Center. Barry attended Emory University between 1994 and 1998 and Cornell between 2006 and 2007.

Joshua M. Tarnoff is a CEO at JDP Therapeutics Inc.

I am an innovative entrepreneur with extensive early-stage drug development expertise in areas including drug formulation, preclinical testing, clinical trials and regulatory strategy. A majority of my drug development experience has centered on the field of opthalmology, and I have also worked in the field of oncology, wound care and dermatology. In my current role as President and CEO of LayerBio, I am leading the development of new biotechnology company with a focus in drug delivery.In addition to experience overseeing R&D and operations in multiple start-up companies, I have consulted for a number of biotech companies providing the following services:- Due Diligence - Technology assessment- Portfolio Prioritization- Product Ideation- Market Analysis and Commercial Strategy - Clinical trial design and IND preparation

Patricia Andrews is an Exec VP/Chief Commercial Officer at Boston Biomedical Inc, Chief Executive Officer at Sumitomo Dainippon Pharma Oncology, and Executive Officer at Dainippon Sumitomo Pharma and is based in Cambridge Lehi, Massachusetts. She has experience at Compass Oncology and has worked as Chief Commercial Officer at INCYTE CORP, Exec VP/COO at Boston Biomedical Inc, and Manager through VP at Pfizer. Patricia attended University of Michigan and Brown University in Providence in the State of Rhode Island & Providence Plantat.

Bastiano Sanna, Ph.D., joined Vertex in 2019 and is the company’s Executive Vice President, Chief of Cell and Genetic Therapies. In this role, Dr. Sanna is responsible for advancing research, development and manufacturing for all of Vertex’s cell and genetic therapy programs, including hemoglobinopathies, Duchenne muscular dystrophy, myotonic dystrophy type 1 and type 1 diabetes. He will also oversee the future Vertex Cell and Genetic Therapies research site, which is expected to open in 2021 at Innovation Square in Boston’s Seaport District. Dr. Sanna was previously the CEO of Semma Therapeutics, which was acquired by Vertex in 2019. Under his leadership, Semma’s pioneering work to develop cell therapy treatments for those living with type 1 diabetes significantly advanced. Prior to Semma, Dr. Sanna was Chief Operating Officer at Magenta Therapeutics, where he was responsible for operations, finance, clinical development and program management. Prior to Magenta, Dr. Sanna served on the leadership team of Novartis’ Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs, where he oversaw clinical, regulatory, CMC and commercial aspects of programs in bone marrow transplant and CAR-T cell therapies. He also served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research, where he was responsible for the global portfolio management of all Novartis’ research programs, from discovery through Phase II across all disease areas. Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.